References
- 1. Mihailov C, Jimborean G, Rascu A, Arghir, OC. The Impact of Tobacco Smoke Exposure on Asthma COPD-Like Patients. J. Environ. Prot. Ecol. 2016;17(4), 1523-1523.
- 2. Dantes E, Man MA, Arghir OA, Alexandrescu D, Trofor A. Risk factors and overlap between asthma and chronic obstructive pulmonary disease. Proceedings of the International Conference on Risk Management, Assessment and Mitigation, RIMA ‘10; WSEAS Conference Book „RECENT ADVANCES IN RISK MANAGEMENT, ASSESSMENT AND MITIGATION” Australia WSEAS Press. 2010;369-373.
- 3. Rascu A, Popa DE, Arghir OC, Naghi E. Effects of Corticosteroid Treatment on Respiratory Muscles Function in Patients with Severe Obstructive Lung Disease, FARMACIA. 2016; 64(6):819-822.
- 4. Biancardi E, Fennell M, Rawlinson W, Thomas PS. Viruses are frequently present as the infecting agent in acute exacerbations of chronic obstructive pulmonary disease in patients presenting to hospital. Int. Med. J. 2016;46, 1160-1165.
- 5. Mohan A, Chandra S, Agarwal D, Guleria R, Broor S, Gaur B, Pandey RM. Prevalence of viral infection detected by PCR and RTPCR in patients with acute exacerbation of COPD: a systematic review. Respirology. 2010;15, 536-542.
- 6. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ. 1995;310:1225-1229.
- 7. Edwards MR, Kebadze T, Johnson MW, Johnston SL. New treatment regimens for virus-induced exacerbations of asthma. Pulm. Pharmacol. Ther. 2006;19, 320-334.
- 8. Cambrea SC, Halichidis S, Mihai CM, Carp DS, Stoicescu RM, Arghir OC. Environmental risk factors for influenza AH1N1 among children in south-east Romania, J. Environ. Prot. Ecol. 2013;14(3):1132-1139.
- 9. Welte T, Miravitlles M. Viral, bacterial or both? Regardless, we need to treat infection in COPD. Eur. Respir. J. 2014;44:11-13.
- 10. Saleh A, López-Campos JL, Hartl S, et al. The Effect of Incidental Consolidation on Management and Outcomes in COPD Exacerbations: Data from the European COPD Audit, PLos One. 2015;10(7), e0134004.
- 11. López-Campos JL, Hartl S, Pozo-Rodríguez F, et al. Antibiotic Prescription for COPD Exacerbations Admitted to Hospital: European COPD Audit. PLos One, 2015;10(4), e0124374.
- 12. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory Viruses, Symptoms, and Inflammatory Markers in Acute Exacerbations and Stable Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 2001;164:1618-1623.
- 13. Oliver BG, Lim S, Wark P, et al. Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages. Thorax. 2008;63:519-525.
- 14. Hendricks MR, Lashua LP, Fischer DK, et al. Respiratory syncytial virus infection enhances Pseudomonas aeruginosa biofilm growth through dysregulation of nutritional immunity. Proc. Natl, Acad. Sci. U S A, 2016;113:1642-1647.
- 15. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ, 1993;307:982-986.
- 16. Green RM, Custovic A, Sanderson G, Hunter J, Johnston SL, Woodcock A. Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study. BMJ. 2002;324:1-5.
- 17. Wark PAB, Tooze M, Powell H, et al. Viral and bacterial infection in acute asthma and chronic obstructive pulmonary disease increases the risk of readmission. Respirology. 2013;18, 996-1002.
- 18. Rewar S, Mirdha D, Rewar P. Treatment and Prevention of Pandemic H1N1 Influenza. Ann. Glob. Health. 2015;81:645-653.
- 19. Pelaez A, Lyon GM, Force SD, et al. Efficacy of Oral Ribavirin in Lung Transplant Patients with Respiratory Syncytial Virus Lower Respiratory Tract Infection. J. Heart Lung Transplant, 2009;28:67-71.
- 20. Liss HP, Bernstein J. Ribavirin Aerosol in the Elderly. Chest. 1998;93:1239-1241.
- 21. Nathan RA, Geddes D, Woodhead M. Management of influenza in patients with asthma or chronic obstructive pulmonary disease. Ann. Allergy Asthma Immunol. 2001;87:447-454.
- 22. Hayden FG, Belshe RB, Clover RD, et al. Emergence and Apparent Transmission of Rimantadine-Resistant Influenza A Virus in Families. N. Engl. J. Med. 1989;321:1696-1702.
- 23. Davies B.E. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J. Antimicrob. Chemother. 2010;65:ii5-ii10.
- 24. Jefferson T, Jones M, Doshi P, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014; 348:g2545.
- 25. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial. JAMA. 2000;283:1016-1024.
- 26. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J. Antimicrob. Chemother. 1999;44:23-29.
- 27. Heneghan CJ, Onakpoya I, Thompson M, et al. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348:g2547.
- 28. Lalezari J, Campion K, Keene O, et al. Zanamivir for the treatment of influenza a and b infection in high-risk patients: A pooled analysis of randomized controlled trials. Arch. Intern. Med.2001;161:212-217.
- 29. Wester A, Shetty AK. Peramivir injection in the treatment of acute influenza: a review of the literature. Infect. Drug Resist. 2016;9:201-214.
- 30. Kohno S, Kida H, Mizuguchi M, et al. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. J. Antimicrob. Agents Chemother. 2010; 54(11):4568-4574.
- 31. Watanabe A, Chang SC, Kim MJ, et al. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin. Infect. Dis. 2010;51:1167-1175.
- 32. Smee DF, Tarbet EB, Furuta Y, et al. Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice. Future Virol. 2013;8:1085-1094.
- 33. Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100:446-454.
- 34. Berry CM. Understanding Interferon Subtype Therapy for Viral Infections: Harnessing the Power of the Innate Immune System. Cytokine Growth Factor Rev. 2016;31:83-90.
- 35. Kim S, Kim MJ, Kim CH, et al. The Superiority of IFN-lambda as a Therapeutic Candidate to Control Acute Influenza Viral Lung Infection. Am. J. Respir. Cell Mol. Biol. 2017; 56(2):202-212.